Apogee Therapeutics Inc.
Apogee Therapeutics Enters Manufacturing Agreement with Samsung Biologics
Summary
On March 10, 2025, Apogee Therapeutics, Inc. announced a strategic partnership with Samsung Biologics Co., Ltd. for the manufacturing and supply of APG777 drug substance for clinical development and potential commercialization. The Master Services Agreement (MSA) and Initial Project Specific Agreement (PSA) were made effective as of February 28, 2025, and will govern the production and supply of the drug substance, including minimum purchase commitments and associated fees. The MSA is set to terminate in February 2035, or upon termination of any applicable PSA, with potential extensions possible. This agreement is a critical step in Apogee's drug development strategy.
Profitelligence Alerts
Get alerts for APGE
Be first to know when Apogee Therapeutics Inc. files with the SEC.
Filing Categories
Advertisement
About Apogee Therapeutics Inc.
Apogee Therapeutics Inc. is a biotechnology company focused on the development of biologic therapies for atopic dermatitis and other inflammatory diseases. The primary purpose of Apogee Therapeutics is to leverage its expertise in immunology and protein engineering to address unmet needs in the treatment of autoimmune and inflammatory conditions. The company is active in sectors such as healthcare and pharmaceuticals, contributing to advancements in medical biotechnology. Apogee Therapeutics plays a significant role in the financial market by advancing cutting-edge therapies in the biopharmaceutical landscape. It engages in research and development efforts to bring innovative biologic medicines to patients, thereby impacting the broader pharmaceutical industry. The company's focus on treating inflammatory diseases aligns with an increasing demand for novel treatments arising from a greater understanding of disease mechanisms and patient needs. By developing specialized biologic solutions, Apogee Therapeutics positions itself as a key player in addressing some of the challenges associated with chronic inflammatory conditions, ultimately pushing forward the boundaries of therapeutic options available to patients worldwide.
Official SEC Documents
Advertisement